Adlai Nortye (ADR) (ANL)
Develops clinical-stage cancer therapies targeting RAS pathways and immune responses.
$16.48
vs last close+0.91 (+5.84%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 49.85% | 26.46M ADS | |
|---|---|---|---|
| 42 holders · as of Jun 30, 2026 | |||
| Insiders | 11.47% | 6.09M ADS | |
| 4 holders · as of Aug 26, 2026 | |||
| Other | 38.68% | 20.53M ADS | |
| remainder | |||
53.08M ADS (1 ADS = 3 ordinary shares) as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The reported float (12.60M, 71.2% free) does not reconcile with the share count, so it is not shown.
13F, as of Jun 30, 2026
42 holders · 26.46M shares · 22 new positions · 31 increased · 7 reduced · 6 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Cormorant Asset Management, LP | 3.98M | 7.49% | +1.08M | Aug 14, 2026 |
| VR Adviser, LLC | 3.21M | 6.05% | 0 | Aug 14, 2026 |
| Balyasny Asset Management L.P. | 3.06M | 5.77% | +2.18M | Aug 14, 2026 |
| Point72 Asset Management, L.P. | 2.14M | 4.03% | +2.14Mnew | Aug 14, 2026 |
| Bioimpact Capital LLC | 1.94M | 3.65% | +1.94Mnew | Aug 14, 2026 |
| Perceptive Advisors LLC | 1.79M | 3.38% | +1.79Mnew | Aug 14, 2026 |
| Casdin Capital, LLC | 1.25M | 2.35% | +711.5K | Aug 14, 2026 |
| Adar1 Capital Management, LLC | 1.02M | 1.92% | +899.9K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| ANL Talent Limited | 7.75% | 9.30M | 13G | Jan 16, 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 6.10% | 9.64M | 13G | Feb 11, 2026 |
| Cormorant Asset Management, LP | 5.19% | 2.90M | 13G | May 15, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 26, 2026 | Xiaofeng Yeofficer: CFO | Sale | 5,667 | $14.25 | 147,757 |
| Aug 24, 2026 | Xiaofeng Yeofficer: CFO | Sale | 6,000 | $13.98 | 153,424 |
| May 13, 2026 | Yang Ludirector, 10 percent owner, officer: CEO | Sale | 10 | $13.18 | 99,990 |
House and Senate disclosures
Not reported.